Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kazia Therapeutics Ltd KZIA

Healthcare Biotechnology
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor... see more

Recent & Breaking News (NDAQ:KZIA)

Kazia Raises A$4.0 Million to Progress R&D Programs

PR Newswire October 27, 2019

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

PR Newswire September 13, 2019

St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

PR Newswire September 12, 2019

Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

PR Newswire July 21, 2019

Kazia calls for greater awareness of the deadliest brain cancer in the US

PR Newswire July 17, 2019

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

PR Newswire May 19, 2019

New positive data from phase IIa trial in brain cancer patients

PR Newswire May 8, 2019

Kazia calls for greater awareness of the deadliest gynecological cancer in the US

PR Newswire May 8, 2019

Kazia calls for greater awareness of the most lethal women's disease in Australia

PR Newswire May 7, 2019

Edison issues ADR update on Kazia Therapeutics (KZIA)

Accesswire April 1, 2019

Kazia Presents Positive Cantrixil Phase I Data at AACR Conference

PR Newswire Europe Non Regulatory April 1, 2019

Kazia Presents Positive Cantrixil Phase I Data at AACR Conference

PR Newswire Asia March 31, 2019

Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting

PR Newswire March 25, 2019

Kazia Share Purchase Plan Raises A$0.8 Million, Taking Total Funds Raised to A$4.2 Million

PR Newswire Europe Non Regulatory November 20, 2018

Kazia Share Purchase Plan Raises A$0.8 Million, Taking Total Funds Raised to A$4.2 Million

PR Newswire Asia November 19, 2018

Progress Update on GDC-0084 Program

PR Newswire Europe Non Regulatory October 29, 2018

Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer

PR Newswire October 22, 2018

Kazia Raises A$3.4 Million to Progress R&D Programs

PR Newswire Europe Non Regulatory October 17, 2018

Cantrixil Phase I Study Progresses To Next Stage

PR Newswire Asia October 10, 2018

John Theurer Cancer Center Enrolls First Two Patients Nationwide for Groundbreaking Phase II Clinical Trial for Glioblastoma

PR Newswire October 1, 2018